Skip to main content

CORRECTION article

Front. Immunol., 21 October 2022
Sec. Vaccines and Molecular Therapeutics

Corrigendum: Co-stimulation with TLR7 agonist imiquimod and inactivated Influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production

Can Li,,,Can Li1,2,3,4Kelvin K.W. To,,,Kelvin K.W. To1,2,3,4Anna J. X. Zhang,,,Anna J. X. Zhang1,2,3,4Andrew C.Y. Lee,,,Andrew C.Y. Lee1,2,3,4Houshun ZhuHoushun Zhu5Winger W.N. Mak,,,Winger W.N. Mak1,2,3,4Ivan F. N. HungIvan F. N. Hung5Kwok-Yung Yuen,,,*Kwok-Yung Yuen1,2,3,4*
  • 1Department of Microbiology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong
  • 2State Key Laboratory for Emerging Infectious Diseases, University of Hong Kong, Pokfulam, Hong Kong
  • 3Carol Yu Centre for Infection, University of Hong Kong, Pokfulam, Hong Kong
  • 4Research Centre of Infection and Immunology, University of Hong Kong, Pokfulam, Hong Kong
  • 5Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong

In the published article, there were errors in Figure 8 as published. The images of ELISPOT for PBS control treatment in Figure 8B, C and D were duplicated. The image of mdLN IgG ELISPOT in IMQ group (Figure 8B) was duplicated with spleen IgM in IMQ group (Figure 8A). The corrected Figure 8 and its caption appear below.

FIGURE 8
www.frontiersin.org

Figure 8 Antibody responses in spleen and mdLN. Mice received intraperitoneal administration of VCI (IMQ 50 µg + VP 10 µg), IMQ (50 µg) or VP (10 µg) or PBS for 3 days, and then were challenged with 10×LD50 of H1N1/415742Md virus. At 3 days after virus challenge, single cells were prepared from spleens and mdLNs. ELISPOT detection of total IgM, IgG, viral specific IgM and viral specific IgG. (A) Total IgM, IgG secreting cells from spleen; (B) Total IgM, IgG spots from mdLN. (C) Viral specific IgM, IgG secreting cells from spleen; (D) Viral specific IgM, IgG secreting cells from mdLN. Data presented are mean of three different experiments for each type of the antibody secreting cells. n = 3. p < 0.05; ††p < 0.01; †††p < 0.001 (compared with PBS group). *p < 0.05; **p < 0.01; ***p < 0.001 (comparing between VCI group with other treatment group).

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: TLR7, imiquimod, inactivated influenza, A(H1N1)pdm09, B cell, peritoneal, mouse

Citation: Li C, To KKW, Zhang AJX, Lee ACY, Zhu H, Mak WWN, Hung IFN and Yuen K-Y (2022) Corrigendum: Co-stimulation with TLR7 agonist imiquimod and inactivated Influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production. Front. Immunol. 13:1053779. doi: 10.3389/fimmu.2022.1053779

Received: 26 September 2022; Accepted: 10 October 2022;
Published: 21 October 2022.

Edited and Reviewed by:

Fabio Bagnoli, GlaxoSmithKlin, Italy

Copyright © 2022 Li, To, Zhang, Lee, Zhu, Mak, Hung and Yuen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kwok-Yung Yuen, kyyuen@hkucc.hku.hk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.